losartan has been researched along with Nephritis in 9 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Nephritis: Inflammation of any part of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 9.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 5.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Costantino, VV | 1 |
| Gil Lorenzo, AF | 1 |
| Bocanegra, V | 1 |
| Vallés, PG | 1 |
| Kim, JY | 1 |
| Son, JW | 1 |
| Park, S | 1 |
| Yoo, TH | 1 |
| Kim, YJ | 1 |
| Ryu, DR | 1 |
| Chin, HJ | 1 |
| Ougaard, ME | 1 |
| Jensen, HE | 1 |
| Thuen, ID | 1 |
| Petersen, EG | 1 |
| Kvist, PH | 1 |
| Ávila, VF | 1 |
| Foresto-Neto, O | 1 |
| Arias, SCA | 1 |
| Faustino, VD | 1 |
| Malheiros, DMAC | 1 |
| Camara, NOS | 1 |
| Zatz, R | 1 |
| Fujihara, CK | 1 |
| Zhu, J | 1 |
| Zhang, Y | 1 |
| Yang, C | 1 |
| Della Penna, SL | 2 |
| Rosón, MI | 2 |
| Toblli, JE | 2 |
| Fernández, BE | 2 |
| Cao, G | 1 |
| Gorzalczany, S | 1 |
| Pandolfo, M | 1 |
| Kim, JM | 1 |
| Heo, HS | 1 |
| Choi, YJ | 1 |
| Ye, BH | 1 |
| Mi Ha, Y | 1 |
| Seo, AY | 1 |
| Yu, BP | 1 |
| Leeuwenburgh, C | 1 |
| Chung, HY | 1 |
| Carter, CS | 1 |
| Chiang, WC | 1 |
| Lin, SL | 1 |
| Chen, YM | 1 |
| Wu, KD | 1 |
| Tsai, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02620306] | Phase 3 | 351 participants (Actual) | Interventional | 2016-02-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for losartan and Nephritis
| Article | Year |
|---|---|
Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.
Topics: Animals; Epithelial-Mesenchymal Transition; HSP70 Heat-Shock Proteins; Humans; Hypertension, Renal; | 2021 |
Role of angiotensin II and oxidative stress in renal inflammation by hypernatremia: benefits of atrial natriuretic peptide, losartan, and tempol.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Cyclic N-Oxides; Humans; Hypernatremia; Losartan | 2015 |
1 trial available for losartan and Nephritis
| Article | Year |
|---|---|
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials, Phase III | 2017 |
6 other studies available for losartan and Nephritis
| Article | Year |
|---|---|
Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Di | 2018 |
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Female; G | 2019 |
Protective effect of 3-n-butylphthalide against hypertensive nephropathy in spontaneously hypertensive rats.
Topics: Albumins; Animals; Antihypertensive Agents; Benzofurans; Blood Pressure; Blood Urea Nitrogen; Drugs, | 2015 |
Different protective actions of losartan and tempol on the renal inflammatory response to acute sodium overload.
Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Blood Pressu | 2010 |
Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi | 2011 |
Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chemokine CCL2; Cytokines; Female; Follow-Up St | 2008 |